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Abstract
Background: Health care costs have increased faster than Consumer Price Index leading to
patients weighing their options of medical treatment and services. One such service, genetic
counseling, has grown 20% annually, in part due to the increased demand of genetic testing.
Oncology care is one need for testing because 5-15% of all cancer diagnoses in the United States
are inherited. Due to the fact that the Affordable Care Act does not cover all genetic counseling
testing needs, and ethnic minorities are less likely to seek testing due to insurance coverage and
costs, an increased effort is needed to reach high risk individuals in medically underserved
population.
Methods: Health care providers in the oncology health practicing in the state of California were
reached through Listservs and asked to fill out a survey provided through Qualtrics. The survey
included practitioner demographics, patient demographics, and an assessment of needs of
oncology patients. The univariate analyses and bivariate analyses were completed using IBM
SPSS Statistics for Windows, Version 26.0.
Results: Twenty-six individual responses were analyzed and plotted. No statistically significant
findings emerged when analyzing the type of insurance a patient had versus patient barriers to
access, nor when analyzing the patient barriers to access by practice size. Participants who work
with medically underserved populations were more likely to cite health insurance and immigrant
status as barriers to adherence.
Conclusion: Barriers exist for the medically underserved population. Due to study limitations
including small sample size, volunteer bias and instrumentation bias, further research is needed
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for a state wide initiative to promote genetics in an underserved population to address
discrepancies in medical care.
Key Words: genetic counseling, genetic testing, health care costs, insurance, underserved
population
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Introduction
Inherited cancer syndromes comprise of 5-15% of cancer diagnoses in the United States
(U.S. Preventive Services Task Force., 2014). One example of inherited cancer syndromes is
hereditary breast and ovarian cancer (HBOC), which is associated with an increased risk for
breast cancer, ovarian cancer, prostate cancer, melanoma and pancreatic cancer. Another
example is Lynch syndrome, a syndrome that increases the risk for colorectal cancer,
endometrial cancer and ovarian cancer amongst others. Carrier rates in the population can range
from 1/40 to 1/400 for HBOC and 1/300 to 1/400 for Lynch syndrome (“Genetic/Familial HighRisk Assessment: Breast and Ovarian.,” 2019; “Genetic/Familial High-Risk Assessment:
Colorectal.,” 2019; U.S. Preventive Services Task Force*, 2005). These carrier rates, among
other health implications, such as personal and family history, make it crucial for individuals
who are at risk for cancer to meet with genetic counselors. Genetic counseling is an important
component of holistic cancer care and can inform treatment, diagnostic, surveillance and
preventative health recommendations.
As genetic testing advances and patients become more aware of available testing, the
demand for genetic counselors will grow and evolve across different areas of employment such
as commercial laboratories, education, public health and policy. As of today, the demand for
genetic counselor services has grown 20% annually since 2013 and will continue to rise due to
the expansion of genetics and genomics into mainstream medicine (Hoskovec et al., 2018). The
importance of genetic testing is becoming more relevant as demand grows for testing for
multiple disorders with genetic etiology outside of cancer syndromes. These disorders include
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Alzheimer’s disease and prenatal diagnostic testing for chromosomal abnormalities (Caughey et
al., 2004; Han & Jemal, 2017; Kieran et al., 2007; Komenaka et al., 2016; Kopits et al., 2011;
Levy et al., 2011). These tests may identify genetic changes and health risks where increased
screening and management is indicated to help mitigate disease.
With the increasing demand for testing, the costs of the tests, the importance of
insurance costs, and the question of an individual having to compensate for the lack of coverage
are all concerns that come into play for a patient. All of these topics contribute to new roles
being undertaken by genetic counselors, one of which is genesurance counseling. This particular
aspect of genetic counseling includes a conversations about the costs and insurance/third party
coverage for genetic testing (Brown et al., 2018). The purpose is to confirm the responsibility of
the financial burdens imposed on the patient, and this will typically be discussed during the
informed consent process. Genetic counselors not only have to take into account the diverse
types of insurances their patients have, they also have to navigate what testing is suggested from
government and private agencies.
Health care costs have increased for the past 40 years faster than the Consumer Price
Index leading to a strain on patients because they are paying for services out-of-pocket (OOP)
due to either being uninsured, or by paying pricey copayments, coinsurance or deductibles (Ubel
et al., 2013). Patients are often having to choose between paying for medical bills or other
necessary expenses which leads to anxiety and stress. This decision is being made by the patient
weighing their willingness to pay (WTP). This measurement is used to assess the value of the
given healthcare option and its value compared to their disposable income, education and
severity of the illness (Kopits et al., 2011). Individuals should not have put their health on the
line because of medical costs.
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To help improve the lives of patients battling cancer and their families’ lives, it is
imperative to be able to reach all patients in need of genetic counseling regardless of insurance
coverage. The first step to being able to provide for all patients, is determining whether or not
there is a lack of genetic counseling and genetic testing in oncology care for underinsured
patients.
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Literature Review
Insurance Coverage Protocol
The Affordable Care Act (ACA) is meant to eliminate cost sharing for preventive
services which includes genetic counseling and testing for certain cancer mutations. However, it
does not cover all genetic testing and counseling costs that some patients might need, and the
ACA does not cover all insurance types (Fox & Shaw, 2015; Han & Jemal, 2017). Specifically,
under Medicare guidelines, current signs or symptoms of cancer must be present for services to
be covered, even when there is a known inherited mutation in the family (Klug, 2019).
Alternatively, the National Comprehensive Cancer Network (NCCN) recommends that genetic
risk assessments should be obtained from qualified professionals for women with a greater than
20 to 25% risk predisposition for breast cancer and for women with a greater than 5 to 25% risk
for ovarian cancer (“Genetic/Familial High-Risk Assessment: Breast and Ovarian.,” 2019). The
United States Preventative Services Task Force (USPSTF) recommends that women with a
positive family history of breast, ovarian, tubal or peritoneal cancer after being properly screened
should see a genetic counselor for possible BRCA testing (U.S. Preventive Services Task Force*,
2005). The American Society of Clinical Oncology (ASCO) recommends genetic testing for
individuals with a personal and family history suggestive of susceptibility, and that these tests
should be adequately interpreted because the results will aid in diagnosis or medical
management. ASCO also recommends that the pre-test and post-test counseling should be
included in the patient’s oncology care (U.S. Preventive Services Task Force*, 2005). Private
companies like Cigna further deviate by requiring patients receive counseling from independent
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genetics professionals before undergoing genetic testing. This is based on the patients’ need to be
fully informed about the complex topics to be able to make informed decisions (Cigna, 2020).
This range of recommendations may result in some patients paying OOP or choosing to not
receive genetic counseling at all.
There is a reason that these agencies deem these risk assessment appointments necessary.
A qualified health care worker provides risk management not only for a patient’s need to be fully
informed but it is also vital to exclude non-carriers with no strong family history of cancer from
intense cancer screening and unnecessary surgery (Willis et al., 2017). This not only helps
decrease the stress and anxiety of going through these undue processes but also saves people
money and potentially benefits insurance companies in the long run.
The Patient’s Need to Pay Out of Pocket
Diverse studies have shown that depending on the testing and the test price, the desire to
pay OOP will vary. In cases where patients knew their chances of developing Alzhiemer’s
disease (AD) was great, over 60% of patients would still ask for testing if it required self-pay.
These patients had already undergone susceptibility testing through volunteering in a research
study and might have been highly motivated in their preference because they were first degree
relatives of AD patients. Their willingness to pay did decrease as the hypothetical test cost
increased from $100 to $1,000, although, this survey might be biased due to homogenous sample
size based on ethnicity, education and income (Kopits et al., 2011). Study subjects desire to
receive testing no matter what the cost might be based on their value to obtain knowledge over
its potential to improve their health. Although there is no treatment for AD, this study showed
the importance of testing for individuals so they could start planning for the future, make
changes in their personal life and potentially prepare family members for the onset of AD. This
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study can also be used to assess other individuals that are weighing their options for testing, such
as cancer patients.
Another study examined women’s opinions on invasive prenatal diagnostic testing for
chromosomal disorders. The study revealed that 45% of those women would be willing to pay
OOP when told the cost would be $1,300, while 18% would not be willing to pay any amount of
money for the testing (Caughey et al., 2004). This survey included a range of ethnicities, ages,
education status and income levels. The WTP did vary between income and education, indicating
that individuals making a greater income and having a higher education status would be more
willing to pay OOP for the prenatal diagnostic testing. The results also varied between
ethnicities, where Asian women were less likely willing to pay for the testing. These women
were also typically at a higher risk for giving birth to an infant with a chromosomal disorder. The
benefit of this type of testing is primarily to improve quality of life for the patients, but the
relative benefit is confounded by income and unfortunately not offered to women as a costeffective option (Caughey et al., 2004). Individuals who have low income and are potentially
underinsured might opt for not testing, which can drastically change medical management when
this study is applied to patients in the oncology field.
A recent study determined the role that financial factors play when accepting clinical
genetic testing. There was a discrepancy in the individuals that would benefit from the testing but
still would choose not have the test done because of cost (Cappelli et al., 1999; Kieran et al.,
2007). As previously noted, financial factors do prohibit testing, specifically in BRCA testing,
but the need for the testing can be life-saving for some individuals. Testing for high-risk women
can be used for tailoring and modifying breast and ovarian cancer risk assessment. These tests
ultimately lead to individuals making decisions about their cancer surveillance, treatment and
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potentially prevention of the cancer (Burke, 1997; Kieran et al., 2007). Over 50% of the
respondents noted that they would not test because they would not be able to afford the cost.
Interestingly, some of the individuals who were surveyed noted that they would still not do
testing even if they could afford it just because their relatives who also needed the test could not
afford the cost (Kieran et al., 2007). These examples specifically looked at genetic testing alone,
but are there also monetary issues with patients’ willingness to receive genetic counseling?
In another case, individuals that have been referred to a genetic counselor to test for
BRCA1 or BRCA2 due to their family history could have the option of undergoing cascade
testing and receive pertinent risk information for themselves and family members. Some of these
patients do not follow up though because of a multitude of barriers including low income and
insurance coverage. Individuals were asked to rate their level of agreement to the following
statements: “my health insurance coverage meets my health care needs,” “not having health
insurance stops me from getting health care services I may need,” and “I am concerned about the
cost of more genetic tests.” This was done to gage the factors that impacted their decision on
whether or not to return to a clinic for genetic counseling and testing. The responses to this
survey were grouped into three categories on their intent to return to a clinic: ‘yes’, ‘no’, and
‘undecided’. Of the ‘no’ group, 11.3% cited that it was due to insurance coverage as well as the
28.5% of the undecided group (Chadwell et al., 2018). These individuals were highly concerned
due to the cost of genetic testing. This cohort of participants noted that a follow-up appointment
would be valuable but still did not intend to return. These cases allowed researchers to further
pinpoint factors influencing non-uptake of testing in various settings and can help to further
develop interventions that would eventually enable individuals to use results for risk
management (Kieran et al., 2007).

CANCER G.C. AND TESTING FOR UNDERINSURED PATIENTS

8

The Effect of Being Underinsured On the Decision Making Process
Decision making is vital part of a genetic counseling session in which a patient is
encouraged to discuss their options, communicate their preferences, and then be guided toward
their best course of action. It is pertinent that patients make informed decisions based on their
ability to afford medical recommended genetic tests (Brown et al., 2018). Patients’ process of
decision making differs between ethnicities and socioeconomic classes. Low income Latina
women have a tendency to allow a health care provider to give more prescriptive advice, which
is the opposite of what is seen in genetic counseling sessions which is patient focused. Latina
women have a tendency to feel confused and may question the genetic counseling session’s
value (Kamara et al., 2018).
To better inform patients and to create an autonomous environment, genetic counselors
are practicing genesurance counseling, a portion of a genetic counseling session that is devoted
to the costs and insurance party coverage of counseling and testing (Brown et al., 2018). As high
as 95% of the counselors in a study, suggested that the genesurance counseling had influence
over the patient’s decision to proceed with testing or not (Brown et al., 2018). The timing of
when counselors would provide the information in combination with the information being given
could be why the decision was influenced on whether or not the patient decided to go through
with testing. Ultimately, this leads to another burden of being underinsured, the patient has to
determine if the costs of testing and counseling are too high, causing many patients to decline
getting testing (Brown et al., 2018; Kieran et al., 2007; Kopits et al., 2011).
Underinsured Individual’s Demographic Representation in Genetic Counseling
The benefits of genetic testing and counseling have been readily documented, but ethnic
minorities are less likely to undergo testing let alone be offered the opportunity of testing
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(Komenaka et al., 2016; Levy et al., 2011). According the the United States Preventative
Services Task Force, it is recommended that “woman whose family history is associated with an
increased risk for deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic
counseling and evaluation for BRCA testing” (U.S. Preventive Services Task Force*, 2005);
high-risk African American women are less likely to receive testing for breast cancer than are
Caucasian women (Levy et al., 2011). One study reported that black women had a 75% lower
chance of receiving referrals for testing and counseling, many of these women being
underinsured or uninsured. This study sparked future investigation of education related
differences and the effect of socioeconomic status on test uptake. Another study determined that
high-risk African American women had one fifth the chance of even pursuing genetic testing,
which unfortunately also indicates that provider behavior is also an important barrier (Armstrong
et al., 2005). One goal might be to also target provider education and outreach efforts to include
additional resources for service delivery infrastructure.
Other minorities that have an increased likelihood of developing breast cancer, such as
Hispanic and Latina women, are less likely to seek testing because of inadequate insurance
coverage and cost (Komenaka et al., 2016). This is alarming because these women would obtain
great benefit to the testing because it is the leading cause of cancer death within the Hispanic
community and it is shown that the demand is higher for younger breast cancer patients. It is
reported that 66.4% of the women who were offered genetic counseling and risk assessment
through a safety net hospital did not have insurance while the rest were underinsured. Seventytwo percent of these women ended up being affected with breast cancer. This safety net hospital
served a large population in Arizona, which included 78% of the minority community
(Komenaka et al., 2016). It is indicated that if testing and counseling are offered, a high
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proportion of patients will participate. The costs of treating patients without insurance was
accomplished by leveraging other resources from other institutions that had greater funding and
resources, which is obviously not sustainable in all settings. An important takeaway from this
study is that a significant proportion of patients who met with a genetic counselor did not need to
undergo genetic testing, which ultimately decreased medical costs. By allowing the patient to
choose whether or not they wanted testing, this decrease in medical cost expenditure benefitted
hospitals and insurance companies.
This problem has been mirrored in other aspects of medical care as well. Barriers that
have inhibited women from seeking postpartum HIV care in low income populations, which
unfortunately mostly affect minority women, are lack of social support outside of immediate
family members, limited transportation access, and experiences of institutionalized stigma
(Buchberg et al., 2015). While insurance might not play as important of a role in their care, the
author's mixed method approach to obtaining the knowledge will be a vital resource for future
research and shows a national problem of health care policy neglecting the lower socioeconomic
class. Future work and research should continue to check for patterns of genetic testing
discrepancies among high risk populations and the impact of policy change (Han & Jemal,
2017).
Underinsured Patients’ Effect On a Genetic Counselor
Genetic counselors are participating more frequently in their role as genesurance
counselors. This role is vital for patients to be able to be informed about the cost of treatments,
testing and overall coverage of services. Being an educated genetic counselor comes at a cost.
Not only do they need to be knowledgeable about billing codes, barriers to payer utilization and
reimbursement, they need to be able to address these issues with patients while still maintaining
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rapport. It is estimated that approximately six minutes or about 10% of a session is spent on
genesurance and over three hours a week on genesurance related topics. These can include
researching coverage plans, determining OOP costs and following up with patients regarding
payment options, which has increased from just 3 years ago (Brown et al., 2018).
While 87% of genetic counselors surveyed find genesurance counseling important and a
necessary part of their job, counselors frequently are left feeling responsible for managing health
care costs which is distracting them as their main role as genetic counselors (Brown et al., 2018).
One quote from the survey that was particularly impactful was:
“I feel like I should be able to provide my patients with relevant information regarding
their genetic testing options without being burdened with the minutiae of insurance and
costs. However, patients cannot make truly informed decisions without knowing the
financial impact of the testing. Unfortunately, I find that genesurance counseling does
impact a session and the rapport established with my patients. I have to take off my
genetic counseling ‘hat’ and instead put on my ‘financial counselor hat’, which is not
my primary role.”
As far as 32% of the genetic counselors surveyed said that covering genesurance negatively
impacted their rapport with patients, leaving both the counselor and the patient uncomfortable.
Often the intentions of the genetic counselor are misconstrued by the discussion of money in a
clinical setting. Although critical in the decision making, insurance topics are complex for both
the counselor and the patient (Brown et al., 2018).
Identifying the Gap in Underinsured Patients in Oncology Care
It has been cited that there are patients that would utilize genetic counseling and genetic
testing if offered, but they are hindered by lack of coverage and increased costs of healthcare. A
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gap in current research exists in California for a statewide initiative to promote genetic
counseling and genetic testing in underserved populations. With the setback of the current
administration and possible changes in the Affordable Care Act, further research is necessary to
determine how to specifically cover patients that do not have complete access to genetic
counseling or genetic testing. This is necessary because it is foreseen that this subset of the
population might continually increase over the years. It is frustrating on many levels because
they should be entitled to all the same healthcare opportunities as insured individuals when it
comes to genetic counseling and genetic testing. Unfortunately, safety net hospitals are not
sustainable in all parts of America. Many of them are not large enough to even incorporate
genetic counseling and testing.
A state-wide initiative was proposed in Massachusetts to promote genetic testing in an
underserved population. They found that individuals from diverse or limited resource settings are
less likely to access genetic testing and counseling and that continued research efforts is
necessary to promote access to genetic testing (Underhill et al., 2017). This study can be an
important guide for future research and implementation of genetic testing and counseling in
states such as California.
Affected individuals that have come in for testing but cannot provide the cost for follow
up and/or patients that have been referred for testing due to a relevant family history but cannot
afford the cost of the testing, still need this pertinent information. Although, effort is needed to
ensure underinsured patients have access to valuable clinical information, it is first important to
find the gap in underinsured individuals in oncology care in California. This research has taken
the initial step by gathering hospital and patient demographic information, purpose of genetic
counseling cancer referrals from professionals practicing in the oncology health care field,
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13

potential barriers to genetic testing and counseling. The goal after analyzing this data and finding
out how often genetic counseling and testing is utilized in underinsured individuals and potential
reasons why it might not be utilized, is helping clarify the need to reach out to this underserved
population and potentially lead to the next steps of a state-wide initiated process to promote
genetic testing and genetic counseling.
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Methods
Participants
Inclusion criteria to participate in this study restricted responses to oncology health care
professionals currently practicing in the state of California. Participants were reached through
different Listservs, including the Southern California Coalition of Genetic Counselors (around
150 members) and the Northern California Coalition of Genetic Counselors (283 members). The
individuals from the Listserv were asked to refer the survey to colleagues in the oncology field,
resulting in snowball sampling.
Baseline Survey
The Claremont Graduate University Institutional Review Board (CGU IRB) reviewed the
study and deemed it as exempt from IRB supervision. Informed consent was obtained at the
beginning of the survey. Then an assessment was given to obtain the demographics of
participants, including variables such as age, gender, race/ethnicity, years of practice, hospital
size and an assessment of genetics attitude. The patients’ demographics included age, gender,
race/ethnicity and insurance coverage. Ultimately the crux of the survey included patient barriers
to adherence to oncology care and the likelihood of referring oncology patients to genetic
counselors for testing. The survey was administered via Qualtrics (Appendix A), and was
available from June 2019 to March 2020. A total of 26 individuals responded.
Quantitative Analysis
All analyses were run using IBM SPSS Statistics for Windows, Version 26.0 (IBM SPSS
Statistics for Windows, 2019). Univariate analyses included the calculation of measures of
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central tendency (e.g. means), dispersion (e.g. SD), frequencies, and valid percentages. Data
were visualized with tables and bar charts. Bivariate analyses included independent samples ttests and chi-square tests of independence to examine the relationships between key variables in
the study. Statistical significance was determined using the 0.05 level of significance, unless
otherwise noted. Supporting values (e.g. degrees of freedom, effect sizes, etc.) were reported
where necessary.
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Results
Data Cleaning
Data cleaning was performed in order to detect invariant or careless respondent answers
and ensure that all participants qualified to participate in the study. A total of 26 subjects
responded to the survey, with all subjects providing at least partial data. No invariant responses
were offered, and all written feedback reflected good-faith answers, so no subjects were
ultimately removed from the dataset.
Demographics
The data set included 26 responses and participant characteristics and patient
demographics are detailed in Table 1. Of these, 96.2% were female, the majority described
themselves as white (65.4%), and were practicing genetic counselors (76.9%). The majority of
patients being seen were in the adult category (19-64 years old), white, female, and had obtained
insurance through their employer.

Table 1
Demographic characteristics of overall sample (n = 25 - 26)
Overall
Demographic

M (SD)

Freq (%)

Practitioners
Age
Years in Practice
Gender
Male
Female
Other
Ethnicity
Asian
Black / African American
Hispanic or Latin American

37.96 (9.96)
9.27 (7.42)
1 (3.8)
25 (96.2)
0 (0)
4 (15.4)
0 (0)
1 (3.8)
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Native Hawaiian or Pacific Islander
White
Biracial
Other
Job Title/Degree
MD/DO/PA Oncologist
Oncology Nurse Practitioner
Oncology Nurse
Genetic Counselor
Other
Patients
Proportion (%) of Patients Seen by Age Group
Pediatrics (0-18)
Adult (19-64)
Older Adults (65+)
Proportional (%) of Patients Seen by Gender
Female
Male
Other
Proportional (%) of Patients Seen by Ethnicity
Asian
Black
Hispanic or Latin American
Native American
Native Hawaiian or Pacific Islander
White
Other
Proportion (%) of Patients Seen by Type of
Insurance Coverage
Self-Purchased
Insurance through employer
Medicare
Medicaid
Other Government
No Insurance

0 (0)
17 (65.4)
3 (11.5)
1 (3.8)
2 (7.7)
2 (7.7)
0 (0)
20 (76.9)
2 (7.7)

2.17 (0.98)
34.73 (16.84)
17.63 (13.10)
80.91 (13.15)
18.83 (12.95)
2.33 (2.31)
15.68 (9.13)
13.63 (17.75)
20.11 (11.17)
0.32 (1.16)
2.11 (3.35)
48.03 (21.94)
0.84 (2.43)

22.36 (24.20)
43.50 (23.50)
20.44 (13.13)
14.00 (23.28)
1.94 (6.28)
0.31 (1.01)

Univariate Analyses
Barriers to adherence.
In order to better understand the barriers to adherence to oncology care that respondents’
patients face, the proportion of respondents citing each of 8 barriers as relevant to their patient
populations was plotted on a bar chart (see figure 1). The responses indicate that the majority
were reportedly due to finances, followed by health literacy, with only 40.9% reporting that
health insurance would be a barrier.
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Figure 1
Barriers cited by respondents (n = 22-23)

Practice characteristics.
In order to better understand the characteristics of respondents’ practices, frequencies and
valid percentages were tabulated (see Table 2). The hospital size varied considerably between
participants. The majority of the participants did not work with medically underserved
population, while no one worked in a medically underserved area.
Table 2
Practice characteristics (n = 17-24)
Hospital Size, Beds
6-49
50-99
100-199
200-299
300-399
400-499
500+
Medically Underserved, Population
Medically Underserved, Area
Referral Type
Internal
External, Clinical Testing
External, Telegenic

n

Valid Percent

0
2
3
5
2
1
4
4
0

0
11.8
17.6
29.4
11.8
5.9
23.5
16.7
0

11
1
1

55.0
5.0
5.0
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Genetics referrals.
In order to better understand the frequency with which respondents order genetics
referrals, means were calculated on a 6-point frequency scale ranging from Very Rarely to Very
Often (see Table 3). The responses indicate that the majority of oncology cases are referred to
genetics due to an early age of cancer diagnosis, a family history of cancer and due to the
specific type of cancer being diagnosed.
Table 3
Characteristics of Genetics Referrals
Indication
Early Age of Cancer Onset
Family History of Cancer
Specific Cancer Tumor Type
Somatic Genetic Test Results
Reproductive Indications

Frequency Made*
M (SD)
5.13 (1.81)
4.75 (1.75)
4.13 (1.73)
3.38 (2.33)
2.13 (1.36)

* Indicated on a 6pt scale where 1 = Very Rarely and 6 = Very Often

Preparation to discuss genetics issues.
In order to better understand respondents’ preparation to discuss genetics issues, means
were calculated on a series of 6-point, self-report items measuring preparation (see Table 4). Of
the 23 respondents, all of them seemed prepared to discuss a variety of genetic issues with their
patients.
Table 4
Preparation to Discuss Genetics Issues (n = 23)
Genetics Issue
Inheritance
Testing for Family Members
Results Disclosure
Medical Management Recommendations

Preparation*
M (SD)
5.83 (0.49)
5.78 (0.67)
5.83 (0.58)
5.70 (0.64)

* Indicated on a 6pt scale where 1 = Very Unprepared and 6 = Very Prepared
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Research Question #1: Does patients’ insurance coverage differ by the barriers cited?
Table 5
Percentage of Patients Covered by Healthcare Plans by Barriers Cited (n = 13-16)
Barrier * Insurance Type

% of Patients Covered
M (SD)
Barrier
Barrier Not
Cited
Cited

t

df

p

Self Purchased Insurance
Transportation 21.3 (24.3)
25.0 (27.0)
-0.25
12
.81
Financial 22.8 (25.5)
20.0 (21.2)
0.14
12
.89
Health Insurance 27.3 (30.8)
17.0 (11.0)
0.71
11
.50
Health Literacy 20.7 (23.3)
28.3 (32.1)
-0.47
12
.65
Language 18.7 (25.9)
29.0 (21.9)
-0.75
12
.47
Culture 18.3 (29.7)
26.4 (18.6)
-0.61
12
.55
Immigrant Status
4.0 (1.4)
26.8 (25.6)
-1.22
11
.25
Employer-Based Insurance
Transportation 43.0 (23.4)
45.0 (27.4)
-0.14
14
.89
Financial 44.4 (25.1)
37.5 (3.5)
0.38
14
.71
Health Insurance 37.9 (27.8)
48.3 (15.7)
-0.83
13
.42
Health Literacy 43.9 (22.6)
41.7 (32.5)
0.15
14
.89
Language 44.2 (23.7)
42.0 (25.6)
0.17
14
.87
Culture 45.1 (26.0)
41.4 (21.7)
0.30
14
.77
Immigrant Status 43.3 (36.7)
41.8 (21.5)
0.10
13
.92
Medicare
Transportation 20.6 (14.7)
20.0 (8.2)
0.07
14
.94
Financial 21.2 (12.6)
15.0 (21.2)
0.61
14
.55
Health Insurance 19.1 (12.0)
23.3 (16.3)
-0.58
13
.57
Health Literacy 20.5 (14.1)
20.0 (10.0)
0.06
14
.95
Language 20.6 (10.9)
20.0 (18.7)
0.09
14
.93
Culture 18.3 (10.3)
23.1 (16.6)
-0.72
14
.49
Immigrant Status 15.0 (13.2)
22.3 (13.7)
-0.82
13
.43
Medicaid
Transportation 17.8 (25.8)
2.5 (5.0)
1.15
14
.27
Financial 13.9 (24.3)
15.0 (21.2)
-0.06
14
.95
Health Insurance 17.7 (30.2)
10.0 (10.5)
0.59
13
.56
Health Literacy 17.2 (24.8)
0 (0)
1.17
14
.26
Language 16.7 (16.9)
8.0 (12.6)
0.68
14
.51
Culture 18.8 (29.4)
7.9 (11.1)
0.93
14
.37
Immigrant Status 38.3 (49.1)
8.7 (10.1)
1.04
2.04*
.41
Uninsured
Transportation
0.4 (1.2)
0 (0)
0.70
14
.50
Financial
0.4 (1.1)
0 (0)
0.45
14
.66
Health Insurance
0.6 (1.3)
0 (0)
1.01
13
.33
Health Literacy
0.4 (1.1)
0 (0)
0.58
14
.57
Language
0.5 (1.2)
0 (0)
0.82
14
.43
Culture
0.1 (0.3)
0.6 (1.5)
-0.89
14
.39
Immigrant Status
0.3 (0.6)
0.3 (1.2)
0.00
13
1.00
* The assumption of the equality of variance was violated, so degrees of freedom were adjusted
a
Hedge’s G could not be computed for these analyses

Hedges’
G
0.15
0.11
0.40
0.30
0.42
0.37
0.93
0.08
0.29
0.44
0.09
0.09
0.15
0.06
0.04
0.46
0.30
0.04
0.04
0.36
0.54
0.67
0.05
0.31
0.31
0.55
0.47
1.38
a
a
a
a
a

0.50
0.00
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In order to determine whether the estimated proportion of patients insured under differing
healthcare plans varied between providers based on the barriers to adherence to oncology care
cited, a series on independent samples t-tests were conducted (see Table 5). While no statistically
significant findings emerged from the analyses (p’s > 0.05), this was anticipated as a likely
outcome given the limited sample size. Interestingly, while no results were statistically
significant, four analyses did yield effect sizes greater than the threshold for Medium-sized
effects (Hedges’ G = 0.50) and two had even larger effect sizes exceeding the threshold for
Large-sized effects (Hedges’ G = 0.80; Cohen, 1988). While care must be taken not to overextrapolate from non-significant findings, this is suggestive that replication with a larger sample
may be warranted and ultimately detect significantly significant findings (Cohen, 1988).

Research Question #2: Do the barriers cited differ by hospital size?
Table 6
Barriers Cited by Practice Size (n = 14)
Barrier
Transportation
Yes
No
Financial
Yes
No
Health Insurance
Yes
No
Health Literacy
Yes
No
Language
Yes
No
Culture
Yes
No
Immigrant Status
Yes
No

Hospital Size, n (valid %)
50-299 beds
300+ beds
7 (77.8)
2 (22.2)

5 (71.4)
2 (28.6)

6 (66.7)
3 (33.3)

6 (85.7)
1 (14.3)

3 (33.3)
6 (66.7)

2 (28.6)
5 (71.4)

8 (88.9)
1 (11.1)

5 (28.6)
2 (71.4)

7 (77.8)
2 (22.2)

3 (42.9)
4 (57.1)

5 (55.6)
4 (44.4)

3 (42.9)
4 (57.1)

1 (11.1)
8 (88.9)

1 (14.3)
6 (85.7)

Χ2
0.09

df
1

Cramer’s V
.07

p*
.77

0.76

1

.22

.38

0.04

1

.05

.84

0.79

1

.22

.79

2.05

1

.36

.15

0.25

1

.13

.61

0.04

1

.05

.85
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In order to determine whether the barriers to adherence to oncology care cited differed
between the largest practices compared to smaller ones, a series of chi-square tests of
independence were conducted. As shown in Table 6, no statistically significant association
between hospital size and barriers cites emerged (p’s > 0.05).
Research Question #3: Do the barriers cited differ for medically underserved populations
versus non-underserved populations?
Table 7
Barriers Cited by Whether Respondents Serve a Medically Underserved Population (n = 23)
Medically Underserved, n (valid %)
Barrier
Transportation
Yes
No
Financial
Yes
No
Health Insurance
Yes
No
Health Literacy
Yes
No
Language
Yes
No
Culture
Yes
No
Immigrant Status
Yes
No

Yes

No

3 (75.0)
1 (25.0)

13 (68.4)
6 (31.6)

4 (100)
0 (0)

15 (78.9)
4 (21.1)

4 (100)
0 (0)

5 (27.8)
13 (72.2)

3 (75.0)
1 (25.0)

15 (78.9)
4 (21.1)

3 (75.0)
1 (25.0)

11 (57.9)
8 (42.1)

3 (75.0)
1 (25.0)
3 (75.0)
1 (25.0)

Χ2
0.07

df
1

Cramer’s V
.05

p*
.80

1.01

1

.21

.31

7.06

1

.57

.008

0.03

1

.04

.86

0.42

1

.13

.52

1.01

1

.21

.32

15.63

1

.84

<.001

9 (47.4)
10 (52.6)
0 (0)
18.0 (100)

In order to determine whether the barriers to adherence to oncology care cited differed by
whether the practitioners work with medically underserved population, a series of chi-square
tests of independence were conducted. As shown in Table 7, two statistically significant
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associations emerged. Specifically, participants who work with medically underserved
populations were more likely to cite health insurance and immigrant status as barriers to
adherence (p’s < 0.05).
Research Question #4: Do the barriers cited differ in medically underserved areas versus
non-underserved areas?
The question asking whether respondents work in medically underserved areas turned out
to be a Constant, with no respondents ultimately working in such areas. As a result, Research
Question #4 could not be explored with this sample.
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Discussion
Our findings show that there are still major barriers for individuals to receive genetic
counseling and genetic testing. Among the barriers that were cited, health insurance was reported
to be a barrier 40.9% of the time, showing that there is a discrepancy for individuals who cannot
afford to pay for health insurance. Evidence on sociodemographic factors, including availability
of health insurance, as indicators for receiving genetic counseling and testing have been
inconsistent in past research (Stamp et al., 2019; Willis et al., 2017). With this in mind, these
specific responses could be due to a variety of reasons. Many of these respondents were
practicing genetic counselors, who are already seeing patients for genetic testing and counseling,
meaning that the patients have already overcome these barriers to follow through with the
appointment. Many of the patients that are being seen needed to have health insurance to even
have an appointment, which imposes bias. Additionally, many of the respondents worked within
areas and with patient populations that did not represent medically underserved individuals.
Knowing that the uptake of genetic counseling and genetic testing has primarily been utilized in
non-Hispanic White, educated females (Stamp et al., 2019), we are missing crucial data from a
wide range of potential patients. Looking within our population and out to the general
population, reducing barriers to accessing testing still needs to be addressed.
The characteristics of genetics referrals might have been skewed because the respondents
were primarily genetic counselors. Genetic counselors are intensively trained to know when to
offer appropriate testing and resources. In accordance to NCCN guidelines, individuals should be
referred to genetics for testing due to the age of diagnosis of specific cancers, if there is a family
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history of cancer, and if specific types of cancer are being seen (“Genetic/Familial High-Risk
Assessment: Breast and Ovarian.,” 2019; “Genetic/Familial High-Risk Assessment: Colorectal.,”
2019) Further analysis is needed to dive into the barriers versus the specific ethnicities of the
patients. Again, if the primary population that is seen in genetic counseling is homogenous, are
more diverse populations being missed for referrals? It is reported that high risk black woman
and other racial/ethnic minorities are less likely to be counseled than high risk white women,
which mirrors racial disparities in cancer care (Komenaka et al., 2016; Levy et al., 2011). This is
despite the fact that Hispanic women with no medical insurance were significantly more likely to
undergo testing (Komenaka et al., 2016). This indicates that many of these individuals are not
having their medical needs met, even though there are clear guidelines for referrals from NCCN.
Efforts to educate providers about these discrepancies and about the benefits of genetic
assessment may further stimulate additional usage in the future.
Due to the majority of respondents being genetic counselors and that the average time in
practice is 9.27 years, it is not surprising that they are prepared to discuss genetic counseling
issues. There are many genetic issues that need to be discussed in oncology genetic counseling to
make sure that patients have all the proper information to make informed decisions. Genetic
counselors and other providers need to be able to provide this information to a diverse group of
individuals, including those with varying education levels. As the demand for genetic counseling
grows, new avenues including video-teleconferencing, are emerging to reach high-risk
underserved individuals outside of major metropolitan areas (Mette et al., 2016). Incorporating
similar technologies may be an effective way to reach all potential patients, which will help
eliminate the disparities in access to services, and genetic counselors need to become
comfortable applying their knowledge within these varying types of sessions.
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No statistically significant findings emerged when assessing the types of insurance
coverage for patients and barriers cited. However, trends were identified that suggest significant
correlations may be obtained if this study were to be replicated with a larger sample. By running
Hedges’ G, a necessary test for smaller sample sizes, we observed medium size effects (Hedges’
G=0.50). There was a medium size effect for Medicare patients and immigrant status (g=0.54).
Majority of Medicare patients in 2017 were White, non-Hispanic individuals (75%) that are most
likely not seeking to immigrate into the United States (Med Pac, 2017). Generally, White, nonHispanic people are not hindered by an immigration status, therefore they would have less
barriers involving immigration while accessing genetic counseling. Another medium size effect
was seen with Medicaid individuals and transportation (g=0.67) and language (g=0.55) as a
barrier to care. Medicaid provides health coverage and services for children, people with
disabilities, and seniors and low-income adults. Many of the populations face financial
difficulties, which would make it difficult for people to rely on transportation to get to and from
medical appointments. The state of California provides Medicaid to over over 5 million
Hispanics, 2 million white, non-Hispanics, 700,000 African Americans, and over 1 million
individuals identified as other (West, Rachel, 2017). With many of these individuals not
speaking English as their primary language, it would be difficult to have medical appointments
in English, let alone the difficulty of overcoming the technical genetic language provided in
genetic counseling sessions. Lastly, there was a medium size effect seen in uninsured individuals
might not have culture as a barrier (g=0.5). It is hard to conclude what caused this because we do
not have data providing information on who these uninsured individuals might be.
There are also some large effect sizes seen when running Hedges’ G (Hedges’ G=0.80).
One large effect size seen is that individuals with self-purchased insurance might not have a
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problem with immigrant status (g=0.93). Again, many individuals that are seen for genetic
counseling are of homogenous demographics. Along with these demographics and the fact that
many of the respondents work for hospitals or facilities that require insurance, it is not surprising
that immigrant status would not be a barrier for these individuals. Another large effect size seen
is that Medicaid individuals might have immigrant status as a barrier to access genetic
counseling services (g=1.38). Over 5 million Hispanics have Medicaid in California (West,
Rachel, 2017), it is likely that many of these individuals are immigrants. This is reflective of the
difficulties immigrants have receiving proper medical care. Although it is important to avoid
erroneous extrapolation with these non-significant findings, further work should be done to
replicate this study with a larger sample size (Cohen, 1988).
While non-significant findings were anticipated in Table 6, examination of Cramer’s V
revealed a moderate-sized effect (Cramer’s V = .30-.49) for Language and small-effects
(Cramer’s V = .10 - .29) for Financial, Health Literacy, and Culture. While care must be taken
not to over-extrapolate from non-significant findings, this is suggestive that replication with a
large sample may ultimately detect different barriers cited across differing hospital sizes (Cohen,
1988).
Barriers did differ for medically underserved populations versus non-underserved
population. First, health insurance was a barrier for all participants that reported working with a
medically underserved population (p=0.008). There is conflicting data regarding
sociodemographic predictors and their indication on whether or not an individual will participate
in genetic counseling (Mette et al., 2016; Stamp et al., 2019; Underhill et al., 2017; Willis et al.,
2017). Our data indicates that there is a barrier, but further studies should be done with a larger
sample size. It should be further analyzed in the state of California to be able to potentially
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implement a state-wide initiative to promote genetic testing to an underserved population.
Second, immigrant status was a barrier for participants that reported working with medically
underserved population (p=<0.001). Knowing that many immigrants are of Hispanic decent,
especially in the state of California and that there are disparities in diagnosis and treatment
outcomes for cancer (Mette et al., 2016), it is vital to be able to reach this community for proper
medical care.
Limitations
The study has important limitations to be considered. First, response rate was limited to
only 26 individuals. Due to the small sample size, we were limited in our ability to achieve
significant findings and, as such, make conclusions. The small sample size could be due to the
attempt to rely on participants to snowball the survey to other qualified individuals instead of
reaching out directly to oncologist or oncology nurses. There should be a better utilization of
Listservs to reach the proper respondents, such as reaching out to groups like the Association of
Community Cancer Centers.
Second, we were limited in our ability to capture information from respondents outside of
the genetic counseling field. The number of genetic counselors responding would not have been
a problem if we were able to get a significant amount of responses from oncology health care
providers in the oncologist field, nursing field, and the nurse practitioner field. This was a
problem because the survey was meant for a wider range of responses, and genetic counselors
were limited in what questions they could even respond to. Also, many of the respondents were
working within facilities that required patients to be insured. Therefore, this data might not be
representative of the current landscape of individuals accessing genetic counseling.
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Third, the crux of the survey could have asked more specific and robust questions to
gather information to assess the needs of oncology patients. There were limited questions asking
about the needs, and something that can be expanded upon in future surveys. Finally, the survey
was run for a limited amount of time. Health care professionals could have been overwhelmed
with work and the current conditions, which could have prohibited them from taking extra time
to fill out a survey. This can be seen by the low response rate of 54.2%, meaning that half of the
individuals that started the survey did not finish the survey.
Future Research
Future research is necessary to be able to implement a possible state-wide initiative to
promote genetic testing in an underserved population. This survey potentially laid the
groundwork but larger sample size should be used. Future research should reach out specifically
oncology professionals and potentially exclude genetic counselors. There could also be further
analysis into these specific barriers, and other barriers that are seen which could be limiting care
to underserved populations. Survey participants could possibly rank these barriers based on the
population that they are seeing in practice. Finally, actual sampling of patient populations should
be utilized as well.
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Conclusion
In conclusion, the results from this study are useful in discovering barriers for attendance
of genetic counseling sessions for medically underserved populations. Due to conflicting reports,
future work is needed to evaluate these barriers in a larger sample size and potentially from
individuals who are not practicing in the genetic counseling field. Continued research efforts
should be devoted to promoting access to genetic testing and counseling in the high-risk
underserved community. This study highlights a need for a state-wide initiative to promote
genetic testing in an underserved population to address the discrepancies in medical care to
underserved populations.
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Appendix A
Qualtrics Survey
Identifying the gap: genetic counseling and testing for underinsured oncology patients.

Start of Block: Consent Form
C1
Thank you for participating in a research project being conducted as part of a Master's Thesis at
Keck Graduate Institute. While volunteering to complete the survey will probably not benefit
you directly, the information you provide will help explore the genetic counseling and genetic
testing needs of underinsured and uninsured oncology patients. Volunteering for this study does
not involve risk beyond what a typical person would experience on an ordinary day and the
survey should take about 20 minutes of your time. Your involvement is entirely voluntary, and
you may withdraw at any time for any reason. If you are uncomfortable answering any question
on the survey, you may leave it blank.
By clicking "Next" you are consenting to take the survey.

o Next
End of Block: Consent Form
Start of Block: Demographic and knowledge based questions for the oncology health care
provider:
1 The following questions aim to assess the demographics and knowledge base of the oncology
health care provider:
Q1 Practice/Facility Name:
________________________________________________________________
Q2 Age:
________________________________________________________________
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Q3 Gender:

o Male
o Female
o Other (Please specify): ________________________________________________
Q4 What race/ethnicity best describes you (select all that apply)?

▢ White, not Hispanic
▢ Black or African American
▢ Hispanic or Latin American
▢ American Indian or Alaska Native
▢ Asian
▢ Native Hawaiian or Pacific Islander
▢
Other (Please specify):
________________________________________________
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Q5 Job Title/Degree:

o MD/DO Medical Oncologist
o MD/DO Surgical Oncologist
o MD/DO Radiation Oncologist
o Oncology Nurse Practitioner
o Oncology Nurse
o Genetic Counselor
o Other (Please specify): ________________________________________________
Q6 Years in oncology practice:
________________________________________________________________
Q7 Where is the location of your practice?

o Zip Code: ________________________________________________
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Q8 What type of hospital do you currently practice? (Check all that apply)

▢ Federal Qualified Health Center
▢ Federally Designated Health Professional Shortage Area
▢ Rural Health Clinics
▢ National Health Service Corps
▢ Migrant Health Centers
▢ Health Care for the Homeless Grantees
▢ Indian Health Service Sites/Tribal Health Sites
▢
Other (Please specify):
________________________________________________
Q9 What licensed bed size is your hospital?

o 6-49 beds
o 50-99 beds
o 100-199 beds
o 200-299 beds
o 300-399 beds
o 400-499 beds
o Over 500 beds
o Other (Please specify): ________________________________________________
o Not applicable
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Q10 Genetics Attitude:Please state your level of agreement with the following statements:
Neither
Strongly
Somewhat
Somewhat
Strongly
Agree
agree or
Disagree
Agree
agree
disagree
disagree
disagree
It is a
physician’s
duty to inform
patients of
genetic tests
when they’re
available

o

o

o

o

o

o

o

Patients with
positive
genetic test
results are at
risk for
insurance
discrimination

o

o

o

o

o

o

o

Genetic tests
for cancer
susceptibility
have too
many
inaccurate or
ambiguous
results

o

o

o

o

o

o

o
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Q11a Genetics Knowledge:What percentage of breast cancer patients have an inherited
susceptibility to breast cancer?

o 5%
o 10%
o 20%
o 30%
o 40%
o Unsure
Q11b What is the approximated increased risk to age 70 of developing breast cancer for carriers
of a predisposing mutation in BRCA1?

o 20%
o 40%
o 60%
o 80%
o 100%
o Unsure
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Q11c Which features of breast cancer are associated with an inherited susceptibility? (Select all
that apply):

▢
▢
▢
▢
▢
▢

Earlier age of onset
Dominant inheritance pattern
Transmission of susceptibility only through females
Characteristic histologic features
Bilateral primary breast cancers
Unsure

Q11d The cancer risks of patients with a negative hereditary cancer genetic test result will
always be reduced down to population risk.

o True
o False
Q11e Which of the following cancer risk assessment model calculates the risks of a patient
carrying a Lynch syndrome mutation?

o Gail
o Claus
o IBIS
o PREMM5
o BRCAPRO
End of Block: Demographic and knowledge based questions for the oncology health care
provider:
Start of Block: Demographic questions for oncology health providers: These questions aim
to asse
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2 The following questions aim to assess the demographics of your patients (please fill out to
the best of your knowledge):
Q12 To the best of your knowledge, how many patients in the following ranges have you seen
during the last month?

▢
▢
▢

Pediatrics (0-18): ________________________________________________
Adults (19-64): ________________________________________________
Older Adults (65+): ________________________________________________

Q13 What percentage of your patients are:

▢
▢
▢

Male: ________________________________________________
Female: ________________________________________________
Other: ________________________________________________
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Q14 What percentage of your patients are:

▢ White, not Hispanic: ________________________________________________
▢
Black or African American:
________________________________________________
▢
Hispanic or Latin American:
________________________________________________
▢
American Indian or Alaska Native:
___________________________________________
▢ Asian: ________________________________________________
▢
Native Hawaiian or Pacific Islander:
__________________________________________
▢
Other (Please specify):
________________________________________________
Q15 Do you work with a population that is designated as medically underserved?
(https://bhw.hrsa.gov/shortage-designation/muap-process). The designation of an area that is
medically underserved is typically determined by the following criteria:
• Percentage of
Population Below Poverty Level
• Percentage of Population Age 65 and Over
•
Infant Mortality Rate
• Ratio of Primary Care Physicians per 1,000 Population

o Yes
o No
Q16 Do you work in an area that is designated as medically underserved
(https://bhw.hrsa.gov/shortage-designation/muap-process) The designation of an area that is
medically underserved is typically determined by the following criteria. • Percentage of
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Population Below Poverty Level
• Percentage of Population Age 65 and Over
Infant Mortality Rate
• Ratio of Primary Care Physicians per 1,000 Population

•

o Yes
o No
Q17 Approximately what percentage of the patients you see at your primary practice have health
insurance?:
________________________________________________________________
Q18 On average, what percentage of patients at your primary practice have the following
insurance options?

▢
Self-purchased insurance:
________________________________________________
▢
Insurance through employer:
________________________________________________
▢ Medicare: ________________________________________________
▢ Medicaid: ________________________________________________
▢
Other Government Program:
________________________________________________
▢ No insurance: ________________________________________________
▢
Other (Please specify):
________________________________________________
▢

Not applicable
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Q19 Approximately what percent of the patients you see at your primary practice qualify for
Medicare?:
________________________________________________________________
Q20 Please indicate your degree of agreement or disagreement with the following statement: "On
an average patient encounter at your primary work setting you experience time pressure”

o Strongly agree
o Agree
o Somewhat agree
o Neither agree nor disagree
o Somewhat disagree
o Disagree
o Strongly disagree
o Not applicable
End of Block: Demographic questions for oncology health providers: These questions aim
to asse
Start of Block: The following questions aim to assess the needs of your oncology patients
(pleas
3 The following questions aim to assess the needs of your oncology patients (please fill out to
the best of your knowledge):
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Q21 What barriers to adherence to oncology care do your patients face? (Check all that apply):

▢ Transportation
▢ Financial
▢ Health Insurance
▢ Health Literacy
▢ Language Barrier
▢ Culture Barrier
▢ Immigrant Status
▢
Other (Please specify):
________________________________________________
Q22 Have you ever referred an oncology patient for genetic testing related to their cancer?

o Yes
o No
o Not applicable
Q23 Approximately what proportion of your patients, per 100, would you say you typically refer
for cancer-related genetic testing?:
________________________________________________________________
Q24 What percentage of patients have access to genetic counseling services and follow through
with a visit to genetic counseling?:
________________________________________________________________
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Q25 Please indicate how often you make genetics referrals for each of the following indications:
Very
Somewhat Somewhat
Very
Often
Rarely
Often
Often
Rarely
Rarely
Family History
of Cancer

o

o

o

o

o

o

Specific Cancer
Tumor Type
Encountered (ex:
carcinoid
tumors,
leiomyosarcoma,
etc)

o

o

o

o

o

o

o
o
o

o
o
o

o
o
o

o
o
o

o
o
o

o
o
o

Early Age of
Cancer Onset
Somatic Genetic
Test Results
Reproductive
Indications
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Q26 Please indicate how prepared you feel to discuss each of the following genetics issues with
your patients:
Very
Somewhat
Very
Prepare Somewha
Unprepare
Prepare
Unprepare
Unprepare
d
t Prepared
d
d
d
d
Inheritance
Testing for
Family Members
Results
Disclosure
Medical
Management
Recommendation
s
Other (Please
specify):
Other (Please
specify):

o
o
o

o
o
o

o
o
o

o
o
o

o
o
o

o
o
o

o

o

o

o

o

o

o
o

o
o

o
o

o
o

o
o

o
o

Q27 Where, if at all, do you access information about the benefits of genetic counseling for
oncology care? (Check all that apply):

▢ Resources/classes provided during school/training
▢ Colleagues
▢ Physicians
▢ Genetic Counselors
▢ Internet
▢
Other (Please specify):
________________________________________________

CANCER G.C. AND TESTING FOR UNDERINSURED PATIENTS

50

Q28 Where do you refer your patients if they need a genetic counselor? (Check all that apply):

▢ Internal referral
▢ External referral- Clinical Setting
▢ External referral- Telegenetic
▢
Other (Please specify):
________________________________________________
▢

Not applicable

End of Block: The following questions aim to assess the needs of your oncology patients
(pleas

